CAR-T cells are highly effective in treating selected blood cancers. However, challenges remain with this new therapy, which was first approved in 2017 in the USA and a year later in Europe for treating acute lymphoblastic leukemia (ALL).
DCVC Bio founders look for more quick returns, less overhyped AI, with new $400 million fund
DCVC Bio, a Silicon Valley area investment firm launched six years ago by a group of tech, bio, and agriculture investors, has raised a new